Amgen closes acquisition of 20.5% stake in BeiGene for $2.8bn

This article was originally published here

BeiGene is a commercial-stage oncology firm focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. Former Amgen global commercial operations executive vice president

The post Amgen closes acquisition of 20.5% stake in BeiGene for $2.8bn appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply